Activating Construct News Today

Acquisition includes HPN328, an investigational delta-like ligand 3 targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors ...

Investegate announcements from Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD)

HARP | Complete Harpoon Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

19.12.2023 - SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral ... Seite 1

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 -- Harpoon Therapeutics, Inc.  , a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a...

Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete...

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 -- Harpoon Therapeutics, Inc. , a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will present interim...

Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile:– 63% ORR, 16% cytokine release syndrome , No ICANS – Phase 1 data set, including recommended Phase 2...

SOUTH SAN FRANCISCO - Harpoon Therapeutics, Inc. , a clinical-stage immuno-oncology company developing novel T cell engagers, today announced dosing of the first patients with small cell lung cancer ...

Going forward, Harpoon said the TriTAC multiple myeloma program will remain exclusively within the company as it plans to complete an ongoing Phase 1 clinical trial with data to support the next phase of development.